Brief: Rhythm Pharmaceuticals Says Six-Month Data Shows Setmelanotide Improves Multiple Endpoints In Pws
13/06/2026 13:06
BRIEF-Rhythm Pharmaceuticals Says Six-Month Data Shows Setmelanotide Improves Multiple Endpoints In Pws June 13 (Reuters) - Rhythm Pharmaceuticals Inc RYTM.O:
RHYTHM PHARMACEUTICALS PRESENTS POSITIVE INTERIM SIX-MONTH DATA FROM PHASE 2 TRIAL OF SETMELANOTIDE IN PATIENTS WITH PRADER-WILLI SYNDROME (PWS) AT ENDO 2026
RHYTHM PHARMACEUTICALS - SIX-MONTH DATA SHOWS SETMELANOTIDE IMPROVES MULTIPLE ENDPOINTS IN PWS AS OF MAY 7, 2026
Source text: ID:nGNX2kNhjB
Further company coverage: RYTM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rhythm Pharmaceuticals
See all newsBrief: Rhythm Pharmaceuticals Announces Appointment Of Manher (Aj) Joshi As Chief Medical Officer
Rhythm's drug shows promise for brain tumor-related weight condition in small study (updated)
Rhythm Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition
Rhythm Pharmaceuticals Q2 net loss narrows on US launch demand